First Mesothelioma Patient Begins Newly Approved Treatment

A mesothelioma patient at West Cancer Center in Memphis, Tennessee, is the first in the country to use NovoTTF-100L, a noninvasive electric therapy treatment, since its approval by the U.S. Food and Drug Administration in May. The FDA’s approval of Novocure’s Tumor Treating Fields device for the treatment of mesothelioma marked the first new FDA-approved treatment option for the rare asbestos-related cancer in more than 15 years. NovoTTF-100L uses a low-voltage electrical field that is distributed with three pads attached to the front and back of a person’s chest. The electrical current is designed to disrupt the inner components of a cancer cell when it divides. It is now approved to treat mesothelioma in addition to chemotherapy, the most used treatment option for the rare cancer. The patient at West Cancer Center will wear the device for 18 hours a day. His doctors are expecting promising results. “We are looking at 97% disease control at year one,” Dr. Moon Fenton, a hematologist at West Cancer Center, told WMC 5 Action News. “So, patients who are using this technology in addition to the chemotherapy actually have stable disease or great response to treatment.” Free Mesothelioma Information Guide, Tailored to You Select the diagnosis you or your loved one is facing and receive a free guide with the right information for you. Get Your Packet ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Publication date: Available online 18 January 2020Source: Redox BiologyAuthor(s): Mohamad Assi, Suzanne Dufresne, Amélie RébillardAbstractIn this paper of the special issue dedicated for the Olympics 2020, we put the light on an exciting facet of exercise-oncology, which may still be unknown to some audience. Accumulating convincing evidences show that exercise reduces cancer progression and recurrence mainly in colon and breast cancer patients. Interestingly, the positive effects of exercise on cancer outcomes were mainly observed when patients practiced vigorous exercise of 6 METs or more. At the molecular ...
Source: Redox Biology - Category: Biology Source Type: research
Authors: Bharadwaj AS, Swamy PM, Mamas MA Abstract Introduction: There are numerous shared risk factors in the etiopathogenesis of coronary artery disease (CAD) and cancer both at the epidemiologic and molecular level. Additionally, the different modalities of treatment of cancer such as radiation, chemotherapy, immunotherapy and hormonal therapies further increase the risk of CAD and acute coronary syndrome. Most large database analysis and single center experiences have shown that cancer patients undergoing PCI are at an increased risk of in-hospital mortality, bleeding repeat revascularization.Areas covered: In ...
Source: Expert Review of Cardiovascular Therapy - Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
Conclusions: Salvage chemotherapy (often with rituximab and radiotherapy), followed by HDT and stem cell transplantation, appears to be the standard real-world treatment for rrPMBCL. However, large prospective and retrospective studies are warranted to improve our knowledge of real-world treatment patterns. PMID: 31951774 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Authors: Annibale B, Esposito G, Lahner E Abstract SUMMARYIntroduction: Atrophic gastritis (AG) is a complex syndrome which arise as consequence of H. pylori infection or in the context of gastric autoimmunity. It often deserves a benign course, but may lead to potentially life-threatening complications: cancer and anaemia. This review aims to address traditional and innovative knowledge on this often under-diagnosed disorder.Areas covered: This review covers clinical presentation, risk factors, diagnosis and management of AG and provides an updated resource for clinicians to get insight in this challenging disorde...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
ConclusionFor advanced endometrial cancer patients, surgery in addition to chemotherapy confers a survival advantage except when optimal debulking cannot be achieved.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
TERMINALLY-ILL cancer patients are stunning medical experts by getting the all-clear after being given an NHS therapy dubbed “the Lazarus treatment”. The “transformational” form of immunotherapy reprogrammes the immune system so that it destroys the cancer, with tumours shrinking within days.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth. In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option. “At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Dear Member of Congress: The 133 undersigned national business, higher education, scientific, patient, and other organizations write to strongly urge you to pass an omnibus FY2015 appropriations bill this year that includes increased investments in scientific research and higher education needed to help close our nation's innovation deficit. Members of the Senate and House from both political parties have highlighted the need to address the innovation deficit. Congress has already taken some preliminary steps in this direction. In most instances, individual appropriations bills considered by the House and Senate Appropri...
Source: ActionBioscience - Category: Science Authors: Source Type: news
More News: Asbestosis | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Hematology | Immunotherapy | Lung Cancer | Medical Devices | Mesothelioma | Neurology | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Skin